Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

21:03 EDT 28 Apr 2013 | News-Medical.net

Pfizer Inc. presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49 years of age.

Original Article: Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

NEXT ARTICLE

More From BioPortfolio on "Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives"

Search BioPortfolio:

Relevant Topics

The Top 100 Pharmaceutical Companies · Latest News · Clinical Trials · Research · Drugs · Reports · Corporate
Top 100 Pharmaceutical Companies 2012 (SCRIP 100 - http://www.scrip100.com/scrip100.html) Rank (2011 in Brackets) Company SEARCH FOR COMPANY IN BIOPORTFOLIO'S BIOCORPORATE DATABASE 2012 pharma sales...

Vaccine · Latest News · Clinical Trials · Research · Drugs · Reports · Corporate
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one...

Advertisement
Advertisement

Searches Linking to this Story